U.S. Markets open in 4 hrs 25 mins

In case you missed it: Digipath's Chief Science Officer Explains Company's New Field Test

Digipath Seeking Patent Protection While DEA Requests Market Research

LAS VEGAS, April 17, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP), is pleased to provide an opportunity to hear more about the Company's ground breaking new field test for cannabis, hemp and CBD samples via an interview with Chief Science Officer Cindy Orser.

(PRNewsfoto/DigiPath, Inc.)

To view the interview click the following link: https://digipath.com/current-projects/

Dr. Orser, PhD and Dr. Philippe Henry, PhD are the driving forces behind the development of the field test which has been created to provide relief and clarity for an array of uses where the type of cannabis product must be quickly and accurately determined using a portable methodology. GroSciences, Inc., Digipath's wholly owned subsidiary is seeking a provisional patent for the field test and will be packaging and validating over the next several weeks.  

High Times recently reported an instance where a fully-compliant hemp shipment was wrongfully seized due to a failure to properly identify the cargo. The DEA is now looking for a field test to avoid such problems. "The field test kit must provide specificity to distinguish between hemp and marijuana. It must be portable and rugged enough to be used in non-laboratory environments or ambient conditions," the notice from the DEA reads.

About Digipath, Inc.

Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, formulations for terpene based products, and brings unbiased cannabis news coverage to the cannabis industry.

Digipath Investor Relations & Financial Media

Integrity Investor Relations
info@integrityir.com
Toll Free: (888) 216-3595
www.IntegrityIR.com

Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/in-case-you-missed-it-digipaths-chief-science-officer-explains-companys-new-field-test-300833634.html